Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 650 phase 1 study in advanced solid tumors
jRCT2031200176Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of sovilnesib in Nonhematologic neoplasms, triple-negative breast cancer (TNBC), High-Grade Serous Ovarian Cancer (HGSOC) and 3 more (3 arms), sponsored by Amgen. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with treatment-emergent adverse events and 5 more. Started Mar 2020; status: completed.
02
Drugs
sovilnesib
03
Conditions
Nonhematologic neoplasmstriple-negative breast cancer (TNBC)High-Grade Serous Ovarian Cancer (HGSOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2031200176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200176.